Clinical TrialJun 10, 2026, 04:02 PM
Celldex to Present Barzolvolimab & CDX-622 Clinical Data at EAACI
AI Summary
Celldex Therapeutics announced three presentations at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, highlighting progress in its barzolvolimab and CDX-622 programs. Two flash talks will present results supporting barzolvolimab's first-in-class profile in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU). A late-breaking poster will feature new first-in-human Phase 1 results for the novel bispecific antibody CDX-622 in healthy volunteers, demonstrating its potential to inhibit KIT signaling in mast cells.
Key Highlights
- Celldex to present three clinical program updates at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress.
- Two flash talks will cover barzolvolimab data in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU).
- Barzolvolimab data will show sustained off-treatment improvement in angioedema in CSU patients.
- A flash talk will validate the Worst Itch Numeric Rating Scale (WI-NRS) as a patient-reported outcome in Cold Urticaria.
- A late-breaking poster will present new first-in-human Phase 1 results for the bispecific antibody CDX-622 in healthy volunteers.
- CDX-622 targets TSLP and mast cells via stem cell factor, highlighting its potential to inhibit KIT signaling.
- Barzolvolimab is currently in Phase 3 studies for CSU and ColdU/SD, and Phase 2 for prurigo nodularis and atopic dermatitis.
Price Impact
More from CLDX